Carter Gould
Stock Analyst at Cantor Fitzgerald
(3.87)
# 666
Out of 5,124 analysts
215
Total ratings
56.69%
Success rate
7.44%
Average return
Main Sectors:
Stocks Rated by Carter Gould
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMGN Amgen | Maintains: Neutral | $305 → $315 | $320.72 | -1.78% | 18 | Nov 6, 2025 | |
| NUVL Nuvalent | Maintains: Overweight | $100 → $112 | $97.94 | +14.36% | 2 | Oct 31, 2025 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $925 → $985 | $1,041.51 | -5.43% | 14 | Oct 31, 2025 | |
| GILD Gilead Sciences | Reiterates: Overweight | $135 | $118.30 | +14.12% | 16 | Oct 31, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $678 → $740 | $763.23 | -3.04% | 21 | Oct 29, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $245 → $250 | $220.18 | +13.54% | 18 | Oct 9, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $535 → $485 | $448.80 | +8.07% | 4 | Aug 5, 2025 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Neutral | $55 | $53.06 | +3.66% | 16 | Apr 23, 2025 | |
| PFE Pfizer | Initiates: Neutral | $24 | $25.17 | -4.65% | 15 | Apr 22, 2025 | |
| PCVX Vaxcyte | Initiates: Overweight | n/a | $46.03 | - | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $85 | $107.44 | -20.89% | 11 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $160 → $165 | $135.99 | +21.33% | 12 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $38.11 | -47.52% | 6 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $190 → $180 | $174.63 | +3.08% | 24 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $60 | $10.58 | +467.11% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3 | $0.73 | +312.60% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $1.32 | +581.82% | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $95 | $61.26 | +55.08% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $25 → $20 | $7.88 | +153.81% | 5 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $73 | $61.83 | +18.07% | 4 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $12 | $1.60 | +650.00% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $1.5 | $2.74 | -45.26% | 6 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $2.25 | $0.10 | +2,150.00% | 4 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $392 → $380 | $153.00 | +148.37% | 1 | Jan 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 → $82 | $101.79 | -19.44% | 5 | Jan 16, 2019 |
Amgen
Nov 6, 2025
Maintains: Neutral
Price Target: $305 → $315
Current: $320.72
Upside: -1.78%
Nuvalent
Oct 31, 2025
Maintains: Overweight
Price Target: $100 → $112
Current: $97.94
Upside: +14.36%
Eli Lilly and Company
Oct 31, 2025
Maintains: Overweight
Price Target: $925 → $985
Current: $1,041.51
Upside: -5.43%
Gilead Sciences
Oct 31, 2025
Reiterates: Overweight
Price Target: $135
Current: $118.30
Upside: +14.12%
Regeneron Pharmaceuticals
Oct 29, 2025
Maintains: Overweight
Price Target: $678 → $740
Current: $763.23
Upside: -3.04%
AbbVie
Oct 9, 2025
Maintains: Overweight
Price Target: $245 → $250
Current: $220.18
Upside: +13.54%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Overweight
Price Target: $535 → $485
Current: $448.80
Upside: +8.07%
Bristol-Myers Squibb Company
Apr 23, 2025
Reiterates: Neutral
Price Target: $55
Current: $53.06
Upside: +3.66%
Pfizer
Apr 22, 2025
Initiates: Neutral
Price Target: $24
Current: $25.17
Upside: -4.65%
Vaxcyte
Apr 22, 2025
Initiates: Overweight
Price Target: n/a
Current: $46.03
Upside: -
Apr 22, 2025
Initiates: Neutral
Price Target: $85
Current: $107.44
Upside: -20.89%
Dec 23, 2024
Maintains: Overweight
Price Target: $160 → $165
Current: $135.99
Upside: +21.33%
Nov 1, 2024
Maintains: Overweight
Price Target: $18 → $20
Current: $38.11
Upside: -47.52%
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $190 → $180
Current: $174.63
Upside: +3.08%
Aug 14, 2024
Maintains: Overweight
Price Target: $200 → $60
Current: $10.58
Upside: +467.11%
Jun 13, 2024
Maintains: Overweight
Price Target: $7 → $3
Current: $0.73
Upside: +312.60%
Jun 11, 2024
Initiates: Overweight
Price Target: $9
Current: $1.32
Upside: +581.82%
May 23, 2024
Maintains: Overweight
Price Target: $100 → $95
Current: $61.26
Upside: +55.08%
Apr 16, 2024
Maintains: Overweight
Price Target: $25 → $20
Current: $7.88
Upside: +153.81%
Feb 29, 2024
Maintains: Overweight
Price Target: $62 → $73
Current: $61.83
Upside: +18.07%
May 5, 2023
Maintains: Overweight
Price Target: $14 → $12
Current: $1.60
Upside: +650.00%
Mar 21, 2023
Maintains: Equal-Weight
Price Target: $2 → $1.5
Current: $2.74
Upside: -45.26%
Aug 16, 2022
Maintains: Equal-Weight
Price Target: $2.5 → $2.25
Current: $0.10
Upside: +2,150.00%
Jan 20, 2022
Maintains: Equal-Weight
Price Target: $392 → $380
Current: $153.00
Upside: +148.37%
Jan 16, 2019
Downgrades: Neutral
Price Target: $75 → $82
Current: $101.79
Upside: -19.44%